Navigation Links
NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
Date:9/7/2007

Program Seeks to Identify microRNA Biomarkers for Overall Survival and Risk

of Melanoma Metastasizing to Distant Sites

REHOVOT, Israel and NEW YORK, September 7 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (NASDAQ: ROSG), a global leader in the field of microRNA and RNAi, announced today it will be working in collaboration with NYU Medical Center to leverage the significant potential of microRNA profiles to develop a diagnostic test for melanoma.

Rosetta Genomics believes its unique diagnostic engine has enabled it to discover the majority of known microRNA sequences for which it has submitted a series of patent applications. With this proprietary engine, Rosetta will screen more than 700 microRNAs (many of which are not publicly available) in order to identify the right signature which will potentially be able to quickly and efficiently find the right prognostic indicator test for harmful melanomas.

While this melanoma diagnostic test is still in the early stages, Rosetta Genomics plans to launch three diagnostic products in 2008 that include a test for cancer of unknown primary ("CUP") and two differential diagnostic tests related to lung cancer. The company will continue gradually to expand its pipeline with more diagnostic and eventually therapeutic applications.

"We see helping cure cancer as an incredibly important responsibility for Rosetta Genomics. Much of our work surrounds discovering microRNA biomarkers, and given how much is known about the connection between microRNA and cancer, we believe that we are in a unique position to advance the fields of cancer diagnosis, prognosis and therapeutics. This collaboration with NYU will give both organizations an opportunit
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Medical College receives $377K to study brain disease
2. Barriers will not stop convergence of medical technologies
3. Medical College team creates website for tracking flu
4. Biomedical engineering conference invites manufacturers
5. Visions: Wade offers straight talk on e-medical records
6. Merge unveils updated medical imaging software
7. Medical College receives $1.4M cancer grant
8. Medical technology firm lands $100K federal grant
9. Doyle outlines spending for Medical College, UWM
10. And the winners in medical design are
11. Manufacturing partnership will move into biotech and biomedical spaces
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cbgl72/middle_east_and ) has announced the ... Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... Middle East & Africa Biomedical Sensors ... a CAGR of 3.26% over the period 2014-2020 ... are adaptable to the genetic formulation of each individual. ...
(Date:8/31/2015)... , Aug. 31, 2015  RXi Pharmaceuticals ... focused on discovering and developing innovative therapies primarily ... announced that the 30-day review period following the ... for ocular indications with the U.S. Food and ... is now active. Logo -  ...
(Date:8/31/2015)... Calif. , Aug. 31, 2015 FLX ... and development of novel cancer immunotherapies, announced today that ... as Chief Executive Officer and William Ho , ... Ho join an experienced management team led by veterans ... Fridman , Ph.D., Chief Scientific Officer; Jay Powers ...
(Date:8/31/2015)... Grove, IL (PRWEB) , ... August 31, 2015 ... ... impurities (PGIs), as a high priority in the drug development approval process. Thus, ... , This year, Regis Technologies, Inc., a Chicago-based CMO, has been hosting ...
Breaking Biology Technology:Middle East & Africa Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts to 2020 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 3RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 4FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 3FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 4Regis Shares Expert Advice on Impurities in Drug Development 2Regis Shares Expert Advice on Impurities in Drug Development 3
... emerge in the world of pesticides and pest control, and ... implications for public health, ensure that this is done safely, ... in a new report. In a study published today ... , scientists from Oregon State University and the European Union ...
... announces that a new market research report is ... Synthetic Biology Industry http://www.reportlinker.com/p0305188/Global-Synthetic-Biology-Industry.html ... market for Synthetic Biology in US$ Million by ... Chemicals, Biotechnology & Pharmaceuticals, and Research & Development. ...
... PARK, N.J., Oct. 4 Shionogi Inc., the ... today announced the U.S. Food and Drug Administration ... extended-release tablets, an extended-release oral formulation for the ... children and adolescents ages 6-17 years. KAPVAY™ is ...
Cached Biology Technology:New approaches needed to gauge safety of nanotech-based pesticides 2New approaches needed to gauge safety of nanotech-based pesticides 3Reportlinker Adds Global Synthetic Biology Industry 2Reportlinker Adds Global Synthetic Biology Industry 3Reportlinker Adds Global Synthetic Biology Industry 4Reportlinker Adds Global Synthetic Biology Industry 5Shionogi Announces FDA Approval of KAPVAY™ - The First and Only Therapy Approved for Use with Stimulant Medication for the Treatment of ADHD 2Shionogi Announces FDA Approval of KAPVAY™ - The First and Only Therapy Approved for Use with Stimulant Medication for the Treatment of ADHD 3Shionogi Announces FDA Approval of KAPVAY™ - The First and Only Therapy Approved for Use with Stimulant Medication for the Treatment of ADHD 4Shionogi Announces FDA Approval of KAPVAY™ - The First and Only Therapy Approved for Use with Stimulant Medication for the Treatment of ADHD 5Shionogi Announces FDA Approval of KAPVAY™ - The First and Only Therapy Approved for Use with Stimulant Medication for the Treatment of ADHD 6
(Date:8/28/2015)... , August 28, 2015 According ... Training Market by Assessment Type (Pen & Paper Based, ... Training, Corporate Learning, Academic Research), Vertical and Region - ... and Training Market to grow from USD 2.4 Billion ... a Compound Annual Growth Rate (CAGR) of 25.6% from ...
(Date:8/24/2015)... , August 24, 2015 The ... ,s largest biometrics manufacturer DERMALOG and its customized solutions ... "2015 African Biometrics Company of the Year Award". DERMALOG is ... Nigeria .   -Cross reference: Picture is ... - On Thursday evening, in ...
(Date:8/20/2015)... , Aug. 20, 2015   Sensory, ... on improving the user experience and security of ... technologies, today announced that its TrulySecure™ ... authentication software to be FIDO Certified™. ... for compliance with the FIDO UAF (Universal Authentication ...
Breaking Biology News(10 mins):Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 2Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 3Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 4Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5
... diesel engine is far from easy. Due to the ... cycles are the same. Furthermore, the measurements are difficult ... injected into the cylinder causes an extra source of ... with an engine adapted for this purpose. Laser ...
... compelling argument for reducing fish harvests the profit motive ... of lower catches for the long-term gain of higher returns ... on fisheries over-exploitation. They say their findings, published in ... cause of over-fishing industry opposition to lower catches ...
... Described as a hotspot of botanical diversity, there are ... Several thousand of them are used by traditional healers ... of problems from the common cold to serious diseases ... are will be the focus of The International Center ...
Cached Biology News:Economists: Reduce fish catch now for bigger net profits later 2Economists: Reduce fish catch now for bigger net profits later 3Study of African traditional medicine will begin world-first clinical trial 2Study of African traditional medicine will begin world-first clinical trial 3